Anavex Life Sciences Corp Adds A Director, Promising News
May 22, 2008 · Filed Under General
Anavex (AVXL.OB) added Alison Ayers, the the Worldwide Commercial Head for Oncology at Pfizer (PFE) to its board. It may be a sign that the company’s prospects are picking up considerably. The firms recently announced that its ANAVEX 7-1037 “has demonstrated its ability to significantly delay the growth of cancerous tumors in patient-derived xenografts during advanced pre-clinical studies.”
The company lost $671,000 in the last quarter compared with a loss of $168,000 last year.
It is hard to imagine a senior Pfizer exec would join up unless the firm was making some demonstrable progress.
Douglas A. McIntyre